A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Pfizer
Pfizer
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
AVEO Pharmaceuticals, Inc.
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
SecuraBio
Novartis
Bristol-Myers Squibb
Telix Pharmaceuticals (Innovations) Pty Limited
Celgene
Novartis
Verity Pharmaceuticals Inc.
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
AstraZeneca
Pfizer
Genmab
Pfizer
Qilu Pharmaceutical Co., Ltd.
CSPC Megalith Biopharmaceutical Co.,Ltd.
Regeneron Pharmaceuticals
Hoffmann-La Roche
University Health Network, Toronto
Shanghai Miracogen Inc.
Newave Pharmaceutical Inc
St. Olavs Hospital
Fondazione Italiana Linfomi - ETS
Novartis
Alexion Pharmaceuticals, Inc.
Chengdu Zenitar Biomedical Technology Co., Ltd
Tesaro, Inc.
Shanghai Junshi Bioscience Co., Ltd.
Celgene
UNICANCER
AbbVie
University College, London
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
University Hospital, Toulouse
Regeneron Pharmaceuticals
BeiGene
University of Aarhus
AIO-Studien-gGmbH
Antengene Corporation
BeiGene
Genmab
Bristol-Myers Squibb
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris